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Aim: Ability to deliver drugs into the cell nuclei can significantly increase the efficacy of cancer therapies,
in particular in the case of multidrug-resistant cancer Results: Polymer nanocarriers based on amphiphilic
thiooctadecyl-terminated poly-N-vinyl-2-pyrrolidone were produced and loaded with a model hydropho-
bic drug, curcumin. Two commonly used loading approaches – emulsification and ultrasonic dispersion –
were found to lead to two different size distributions with distinctively different biological effect. While
nanocarriers produced via the emulsion method penetrated cells by dynamin-dependent endocytic mech-
anisms, sub-100 nm dispersion-produced nanocarriers were capable of crossing the membranes via bio-
logically independent mechanisms. Conclusion: This finding opens an intriguing possibility of intranuclear
delivery by merely tailoring the size of polymeric carriers, thus promising a new approach for cancer ther-
apies.
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Nanoformulated drug-delivery systems based on various nanoncarriers – liposomes, micelles, nanoparticles, etc. –
are rapidly becoming the mainstream approach in medicine, in particular, cancer therapy. They offer a number of
advantages compared with systemical application of drugs, including prolonged circulation time, ability of cell-
specific targeting through passive and active mechanisms, and controlled drug release [1]. As a result, nanocarriers
protect their cargo from degradation, increase the efficacy of drugs and reduce toxicity to healthy tissue and hence
unwanted side effects. Since most of the anticancer drugs attack cell DNA, the ability to penetrate cell nuclei can
significantly increase the therapeutic efficacy. This becomes particularly important for treatment of multidrug-
resistant cancer, since low molecular drug released in cytoplasm can be still cleared of the multidrug-resistant
cells [2].
Cellular uptake of nanoparticle carriers usually occurs through endocytic pathways [3,4]. Briefly, a particle that
comes into contact with the cell exterior becomes engulfed by the cell membrane, forming an invagination, which
afterward separates from the membrane as a vesicle and transports its cargo to various intracellular destinations.
Most of the time, particles are treated by the cell as foreign objects and transported to lysosomes causing degradation
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and loss of activity [5,6]. In this respect, the uptake of nanoparticle carriers [7–9] containing pharmaceutically active
substances by cells through different mechanisms is of considerable interest as it can ensure delivery of therapeutically
active substances to the specific cell compartments, in particular, the nucleus, bypassing the endosomal pathway [10].
Liposomes or micelles formed by amphiphilic compounds are commonly used as nanoparticle drug carriers.
In this regard, poly(ethylene oxide) [11], poly(L-lactide) [12], poly(epsilon-caprolactone) [13], poly(lactic-co-glycolic
acid) [14] and poly-N-vinyl-2-pyrrolidone (PVP) [15–21] have gained widespread acceptance. Intranuclear drug
delivery represents a particular challenge, since transport into a nucleus is strictly controlled by nuclear pore
complexes [22]. Traditionally, viruses [10,23–26], liposomes [10,26] and complexes with proteins, interacting specifically
with the nuclear membrane, for example, nucleoplasmin [27] and the TAT penetrating peptide [28], are used to
deliver pharmaceutically active substances and genetic material to cell nuclei. In particular, DNA viruses, which
are naturally adapted for penetration into a nucleus, such as the adenovirus [23,24] and the simian vacuolating virus
40 [25], have been reported to deliver genetic material to a cell nucleus. Although the use of DNA viruses ensures
high translocation efficiency, significant risks associated with viruses limit the applicability of this approach for
therapeutic purposes [10,26]. On the other hand, the use of nonviral methods for the delivery of pharmacologically
active substances is in general associated with carrier lability [10,26].
Nanocarriers based on amphiphilic poly-N-vinyl-2-pyrrolidones are of particular interest for drug delivery, some
of them being already approved for clinical studies [29]. We have previously shown that amphiphilic derivatives of
poly-N-vinylpyrrolidone can be used both to increase liposomal membrane stability [30] and construct self-assembled
nanocarriers for various low-molecular [31] and high-molecular [32] model hydrophobic drugs. More importantly,
our studies have shown that the amphiphilic PVPs and nano-scaled PVP drug carriers are biocompatible since they
possess low toxicity [33], do not influence blood components and their properties [34] and decrease side toxicity of
model pharmacologically active substances [35].
In this study, we introduce the use of an amphiphilic poly-N-vinyl-2-pyrrolidone containing a thiooctadecyl
end-group (PVP-OD) as an adaptable nanocarrier of biologically active compounds. The PVP-OD was synthe-
sized via the radical polymerization of N-vinyl-2-pyrrolidone using azobisisobutyronitrile (AIBN) to initiate the
polymerization and octadecyl mercaptan as the chain transfer agent. Curcumin was selected as model hydrophobic
pharmaceutically active substance primarily due to its fluorescence properties and lack of toxicity, but also because of
its established antioxidant [36–39], anti-inflammatory [38,40] and anticancer activity [41], which have drawn significant
interest to the compound, in particular, in a nanodispersed form. We demonstrate that we can tailor the size of the
PVP-OD nanoparticles by simple means and that, depending on the size of these nanoparticles, the delivery system
exhibits two distinct mechanisms of cell penetration via endocytosis and by diffusion through the cell membrane.
In the latter case, curcumin was observed in the nuclei of the U87 glioblastoma cells and CRL 2429 fibroblasts,
which generally opens the possibility for intranuclear drug delivery. The possibility of using sub-100 nm carriers
formed by amphiphilic polymers to deliver therapeutic compounds to cell nuclei presents a fundamental new result.
Materials & methods
Materials
N-vinylpyrrolidone, 2,2′-Azobisisobutyronitrile, 1,4-dioxane were obtained from Acros (Geel, Belgium). Octadecyl
mercaptan, curcumin, 1,6-diphenyl-1,3,5-hexatriene (DPH), dynasore (3-Hydroxy-naphthalene-2-carboxylic acid
(3,4-dihydroxy-benzylidene)-hydrazide), Wortmannin from Penicillium funiculosum ((1S, 6bR, 9aS, 11R, 11bR)-
1-(methoxymethyl)-9a, 11b-dimethyl-3, 6, 9-trioxo-3, 6, 6b, 7, 8, 9, 9a, 10, 11, 11b -decahydro-1H-furo[4, 3,
2-de]indeno[4, 5-h]isochromen-11-yl acetate) and the Hoechst 33258 (4-[6-(4-Methyl-1-piperazinyl)[2,6’-bi-1H-
benzimidazol]-2’-yl]phenol trihydrochloride) were purchased from Sigma-Aldrich (MO, USA). All chemicals were
used without further purification unless otherwise specified. All solvents and components of buffer solutions were of
analytical grade and were used as received. A Milli-Q Plus Water Purification System (Merck, Darmstadt, Germany)
was used for preparation of deionized water, which was used throughout the experiments. 1H NMR and 13C NMR
spectra of the products were obtained using an Avance Bruker DPX-300 NMR (Bruker, MA, USA) spectrometer
in deuterated dimethyl sulfoxide. Chemical shifts were reported as δ in units of p.p.m. referenced to the residue
solvent peak. IR spectra were obtained on a Nicolet-380 spectrometer (Thermo Fisher Scientific, MA, USA) in KBr
tablets. Fluorescence spectra were obtained with a Hitachi 650-10S spectrofluorometer (Hitachi, Tokyo, Japan).
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Synthesis & characterization of PVP-OD
Thiooctadecyl poly-N-vinyl-2-pyrrolidone (PVP-OD) was synthesized and characterized as has been reported
earlier [42] (see Supplementary Data for full detail).
The critical micelle concentration was determined by fluorescence spectroscopy using DPH as the fluorescent
probe at excitation wavelength λex = 366 nm and emission wavelength λem = 433 nm [43].
Preparation & characterization of PVP-OD colloidal particles
Two different preparation procedures, based on emulsification and ultrasonic suspension were employed to prepare
curcumin-loaded PVP-OD nanocarriers. In the suspension approach, the amphiphilic PVP-OD was initially
dispersed in water (0.1 g/ml) while curcumin was dissolved in acetone (0.01 g/ml). Equal volumes of the polymer
and the curcumin solution were then mixed under ultrasonic excitation (CV33 Sonics Vibracel, Sonics & Materials,
CT, USA) in an ice bath. The samples were then rapidly frozen with liquid nitrogen and lyophilized.
To produce particles using the emulsion approach, a solution of curcumin in chloroform was initially prepared
(0.01 g/ml). The curcumin solution was added dropwise to a dispersion of the amphiphilic PVP-OD in water
(0.1 g/ml) under ultrasonic treatment in an ice bath. The chloroform was then evaporated under vacuum in a rotary
evaporator (IKA RV10 + HB10 Digital, IKA Works, NC, USA) and the resulting solution frozen in liquid nitrogen
and lyophilized. It should be noted that under these conditions no insoluble residues were observed, indicating
that we operate below the loading capacity of PVP-OD nanocarriers. Determination of curcumin loading degree
in PVP-OD nanoparticles is reported in the Supplementary Data.
In order to remove the fraction of small-diameter particles, the solution of curcumin-loaded nanocarriers via
the suspension approach was filtered using an Amicon centrifugal filter device (Merck Millipore) with a molecular
weight cut-off of 30 kDa according to the manufacturer’s guidelines.
For subsequent experiments, the lyophilized particle powders were dispersed in deionized water (0.02 g/ml). In
all cases, particle size distribution was determined by nanoparticle tracking analysis (NTA) using a Nanosight LM10
(Malvern, UK) instrument equipped with a 642 nm laser and a camera. The original particle suspension was diluted
with deionized water to a concentration of 1 mg/ml prior to measurements; the temperature was continuously
monitored by a thermocouple and was typically about 25◦C. Briefly, during the measurement, the solution was
illuminated with a laser beam, and the motion of all particles within the field of view of an optical microscope was
recorded with a video camera and tracked by the instrument software. Based on the obtained Brownian motion
trajectories, the hydrodynamic diameter of each particle was evaluated and the particle size distribution was plotted.
Each sample was measured for 160 s at 30 frames per second; the measurements were performed in triplicate and
averaged. The obtained number distributions were analyzed to obtain the mean size and standard deviation (SD).
The morphology of the polymeric nanoparticles was analyzed by transmission electron microscopy (JEOL JEM-
2100, Jeol, Tokyo, Japan) at accelerating voltage of 120 kV. A minute quantity of the PVP-OD nanoparticle
suspension was deposited on copper grid covered with 0.2% polyvinyl formal. Excess liquid was removed by filter
paper and the grids were dried at room temperature.
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Figure 1. Fluorescence emission intensity of DPH
(λex = 366 nm/λem = 433 nm) as a function of the
concentration of the PVP-OD block copolymer in water
at 25◦C. The arrow indicates the onset of the formation
of DPH-loaded PVP-OD nanocarriers.
a.u.: Arbitrary units.
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Figure 2. Size distributions (number distribution) for emulsion- and suspension-produced nanocarriers obtained
using nanoparticle tracking analysis (NTA). The solid lines show size distributions (number distribution) of the
curcumin-loaded PVP-OD micelles obtained by (A) the emulsion approach and (B) by the suspension approach. The
dashed line shows a typical distribution obtained after filtration of the nanocarriers produced by the suspension
method using a 30 kDa molecular weight cut-off centrifugal filter. The curves are normalized to the peak value.
a.u.: Arbitrary units.
ζ-potential of the obtained carriers is determined using Zetasizer Nano Z&S (Malvern Instruments Ltd, Malvern,
UK). The measurements were carried out at 25◦C and pH 7.4 (phosphate-buffered saline [PBS]) using disposable
folded capillary cells. The measurements were performed in triplicate.
Atomic force microscopy (AFM) visualization of the nanocarriers was performed using a Multimode Nanoscope
IIIA (Bruker) operating in a tapping mode. Soft OMCL-AC240TS (Olympus, Tokyo, Japan) and HA-NC
(ScanSens, Hamburg, Germany) cantilevers with nominal spring constants of 2 and 3.5 N/m, respectively, were
used for the measurements. Briefly, freshly cleaved muscovite mica pieces, ca. 1 × 1 cm2, were treated with
(3-aminopropyl)trimethoxysilane (Sigma-Aldrich) in vapor phase (see [44] for more detail) to create a positively
charged surface. Next, a solution of curcumin-loaded nanocarriers was incubated on top of the functionalized mica
for 5–10 min. Then the mica plates were rinsed with deionized water, dried under nitrogen stream and imaged in
AFM. The obtained images were processed using built-in Nanoscope as well as WSxM v.5 [45] software.
Cell cultures & cell uptake studies
The human glioblastoma-derived cell line (U87, ATCC no. HTB-14) and primary human fibroblasts (ATCC no.
CRL 2429) were cultured in growth medium consisting of Dulbecco’s modified eagle medium (F12), basal medium
supplemented with 100 U/ml penicillin, 10 mg/ml streptomycin and 10% fetal bovine serum. The cells were
maintained in culture flasks (75 cm2, Greiner Bio One, Germany) in a standard incubator at 5% CO2 and 37◦C.
For the cell uptake studies, the cells were seeded into 96-well polystyrene plates at a density of ca. 5000 cells/cm2.
For each cell type, three different experimental conditions were accessed: a negative control, a dynasore-treated
group and a wortmannine-treated group. Dynasore blocks dynamin-dependent endocytosis by scission of endocytic
vesicles [46], while wortmannin is an inhibitor of the receptor-mediated endocytosis of the cellular PI3-K [47]. 24 h
after seeding, the cells were washed with PBS and then preincubated for 15 min with the Hoechst 33258 fluorescent
DNA-binding dye dissolved in the cell medium at a ratio of 1:1000 and subsequently washed with the medium [48].
The cells were then exposed to the inhibitor solutions (12.5 μl dynasore in 1 ml of medium [80 mM] and 0.11 μl
of wortmannin in 1 ml of medium [100 nM]) at 37◦C for 30 min. Wells without inhibitor were incubated with
growth media for the same period of time. Finally, the cells were treated with 150 μl of curcumin-loaded PVP-OD
nanocarriers (0.13 mg/ml in medium) for 5 min for the nanocarriers stemming from the suspension approach
and 10 min for nanocarriers stemming from the emulsion approach. To monitor the uptake process, the cells were
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Figure 3. Transmission electron microscopy micrographs of curcumin-loaded PVP-OD nanoparticles. Micrographs (A
& C) illustrate nanoparticles produced by the suspension method, while (B & D) nanoparticles produced by the
emulsion method.
washed three-times with PBS and then imaged using an Axio Observer.Z1 inverted microscope (Zeiss, Oberkochen,
Germany).
Cellular uptake of curcumin was quantified as relative fluorescence intensity at the curcumin emission wavelength
per cell, determined by the ratio of the number of bright pixels above a certain threshold (corresponding to the
background) in the curcumin fluorescence channel (excitation 493 nm and emission 517 nm) to that in the Hoechst
channel (excitation 353 nm and emission 465 nm) using Zen Lite image-processing software (Zeiss, Oberkochen,
Germany) and MATLAB (MathWorks, MA, USA) [49].
The distribution of curcumin with respect to cell nuclei was analyzed by calculating fluorophore colocalization [50]
in the curcumin and Hoechst fluorescence channels. The calculations were performed using coloc2 plugin to ImageJ
processing software [51].
Results & discussion
The amphiphilic thiooctadecyl terminated poly-N-vinyl-2-pyrrolidone (PVP-OD) used in this study was syn-
thesized by radical polymerization of N-vinyl-2-pyrrolidone using AIBN as radical chain initiator and octadecyl
mercaptan as chain transfer agent according to previous reports [42,52]. Nuclear magnetic resonance and IR spec-
troscopy were employed to fully characterize the produced polymer (see Supplementary Data for full synthesis and
characterization).
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Figure 4. Atomic force microscopy (AFM) visualization and analysis of nanocarriers. Curcumin-loaded nanocarriers produced by the
suspension method are deposited on mica surface and visualized with AFM (A). To evaluate the size distribution of the produced
nanocarriers, deposition with a lower coverage was obtained (B), where the particles are well separated and can be identified and
measured using WSxM flooding procedure (C). The resulting size distribution obtained after processing of ten different low-coverage
images is shown (D).
Based on the chemical structure of PVP-OD we can assume that the radicals produced by the thermal decom-
position of AIBN react with the octadecyl mercaptan to form thiooctadecyl radicals which in turn can react with
the monomer N-vinyl-2-pyrrolidone causing its polymerization. In view of the high activity of mercaptans with
respect to radicals, the termination of the resulting polymer chain is expected to occur almost exclusively by transfer.
End-group analysis [42] revealed a low number average molecular weight, equal to 6050 Da for the PVP-OD. The
formation of low molecular weight polymers is consistent with the high activity of octadecyl mercaptan in the
chain transfer. The presence of the thiooctadecyl end-group is further confirmed by the ability of the synthesized
compound to form self-assembled nanoparticles at concentrations above 0.065 mmol/l in aqueous media in the
presence of DPH which was used in the present study as a fluorescent hydrophobic marker (Figure 1).
The PVP-OD nanocarriers were found to successfully solubilize the highly hydrophobic curcumin which was
used as a model pharmaceutically active component in the present study. Two loading techniques commonly used
in literature – the emulsification and the ultrasonically-assisted suspension – were employed to prepare nanocarriers
and found to lead to different size distributions of the nanocarriers shown as solid lines in Figure 2A and B. NTA
measurements revealed that the curcumin-loaded nanocarriers prepared using the emulsion approach exhibit a
broad, rather symmetric hydrodynamic diameter distribution with a median at 170 nm, mean diameter of 200 nm,
SD of 90 nm and practically no sub-50 nm particles present (Figure 2A). On the other hand, the suspension method
led to a strongly asymmetric size distribution peaked at 30 nm with a mean diameter of 73 nm, SD of 56 nm
and majority of particles in sub-50 nm range (Figure 2B, solid lines). In both cases, according to measurements,
the obtained particles were slightly negatively charged with ζ-potential of -4.0 ± 0.3 mV. Transmission electron
microscopy pictures of PVP-OD curcumin-loaded nanoparticles show that their shape is close to spherical with
a diameter below 100 nm for the suspension method and about 200–300 nm for the emulsion (Figure 3). This
agrees with the particle size distributions obtained using nanoparticle tracking analysis.
The size distribution of curcumin-loaded nanocarriers was further visualized and evaluated using AFM. A
representative topographic image showing nanocarriers deposited on mica at high density is shown in Figure 4A.
To evaluate the size distribution, a lower density deposition was made and ten different images similar to Figure 4B
were analyzed. Each image was processed using the flooding procedure of WSxM to determine the center of each
micelle and its height, as illustrated in Figure 4C. This yielded a distribution shown in Figure 4D with a mean
height of 2.7 nm and SD of 0.9 nm. It can be seen that the micelles collapse when deposited on the surface and
the hydrodynamic diameter of the nanocarriers determined by NTA is significantly larger than the size of collapsed
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Figure 5. Kinetics of in vitro uptake of curcumin-loaded PVP-OD nanocarriers by U87 (A & B) and CRL 2429 (C & D)
cells. Panels (A) and (C) show the uptake of the emulsion-produced nanocarriers; panels (B) and (D) correspond to the
nanocarriers produced via the ultrasonic-dispersion route. In all panels – 1: uptake without endocytosis inhibitors;
2: uptake in the presence of wortmannin; and 3: uptake in the presence of dynasore. Standard error is shown for each
data point.
micelles visualized by AFM. This can also explain high penetrative ability of the nanocarriers observed in cell
studies.
The curcumin-loaded PVP-OD micelles were used for the in vitro studies of nanoparticle uptake by U87
glioblastoma and CRL 2429 fibroblast cells. When the nanocarriers produced by the emulsion method were
introduced into the cell cultures under study in the absence of endocytosis inhibitors, a slow increase in the relative
fluorescence intensity of curcumin with time was observed whereas in the presence of dynasore, it remained constant
(Figure 5). Since the nanoparticle carriers used in the present study did not possess any specific receptor-targeting
moieties, no inhibitory effect was expected in the presence of wortmannin, which blocks the receptor-mediated
endocytosis. The blocking effect of dynasore was clearly visible in both fibroblast and glioblastoma cultures
(Figure 5A & C).
These observations clearly indicate that the uptake of curcumin-loaded PVP-OD nanocarriers produced by
the emulsion approach mainly proceeds through dynamin-dependent mechanisms of endocytosis. This is also
confirmed by the presence of a significant amount of curcumin-labelled endosomes in U87 (Figure 6A) and
CRL 2429 cells (Figure 6B). It should be noted that the obtained micrographs indicate the presence of the
curcumin-loaded PVP-OD nanocarriers in the interior cytosolic compartments of the U87 (Figure 6A) and CRL
2429 (Figure 6B) cells, while the nuclei show no emission in the curcumin channel indicating that they are not
permeable by these nanocarriers. Colocalization analysis of curcumin and the nucleic stain (Hoechst channel)
shows that the two dyes are located in different compartments without any significant overlap: as shown by the 2D
intensity histograms (right column in Figure 6), bright pixels in the curcumin channel correspond to dark ones in
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Figure 6. Uptake of curcumin-loaded nanocarriers by U87 and CRL 2429 cells. Fluorescence images showing: U87 (A
& C) and CRL 2429 (B & D) cells after incubation with curcumin-loaded PVP-OD micelles produced by the emulsion (A
& B) and suspension (C & D) methods. 2D-histograms show colocalization of fluorophores in curcumin (517 nm,
yellow) and Hoechst (465 nm, blue) fluorescence channels and the respective Pearson correlation coefficient R.
the Hoechst channel and vice versa leading to a specific rectangular shape of the histogram. This confirms that the
emulsion-produced curcumin nanocarriers are mainly localized in the cytoplasm and cannot penetrate the nuclei.
Similarly, both the U87 and CRL 2429 cell lines were shown to uptake the smaller diameter nanoparticles
prepared via the suspension approach. However, as shown in Figure 5, the presence of endocytosis inhibitors do not
affect the nanocarrier uptake kinetics. Extremely fast uptake was observed with the maximum relative fluorescence
reached within 5 min for both the reference samples and those exposed to dynasore and wortmannin. Furthermore,
in this case, curcumin was observed throughout the cellular compartments, for example, that a particle subfraction
was also present in the nuclei (Figure 6C & D). Notably, no significant intensity change in the curcumin fluorescence
channel is observed at the nuclei location as compared with the emulsion-produced nanocarriers (cf. panels A &
C, and B & D in Figure 6). This conclusion is supported by colocalization analysis showing a partial overlap
of curcumin and nucleic stain fluorescence channels for both CRL 2429 and U87 cell lines. While curcumin is
present in some cell compartment with no nucleic stain (lower branch in the 2D intensity histogram), there is also
a significant population of pixels with high intensity of both curcumin and nucleic stain.
Further evidence for different internalization of the suspension and emulsion produced nanocarriers in CRL
2429 and U87 cell lines, is provided by 3D fluorescence images consisting of 50 z-stacked layers (Figure 7). The
figure shows the image plane at mid height together with two vertical cross-sections passing through the nucleus
of one of the imaged cells. It can be clearly seen that in the case of emulsion-produced nanocarriers, curcumin is
not present inside the nuclei of CRL 2429 and U87 cells, while in the case of suspension-produced nanocarriers,
curcumin patches are observed inside the nuclei in all the cross-sections.
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Figure 7. 3D fluorescence images show CRL 2429 (A & C) and U87 (B & D) cells incubated with a 1 mg/ml solution of
curcumin-loaded PVP-OD nanocarriers for 30 min. Images in panels (A) and (B) show cells treated with nanocarriers
produced by the suspension method, panels (C) and (D) correspond to nanocarriers obtained by the emulsion
method. The images were obtained by superimposing the Hoechst (465 nm, blue) and curcumin (517 nm, orange)
fluorescence channels, with exposure times of 100 and 700 ms, respectively. Stripes on the right side and above the
images show the vertical cross-section passing through the nucleus of one of the cells. The blue and white arrows
indicate the respective intranuclear and extranuclear compartments in the main panel and cross-sections.
The ability of the sub-100 nm nanocarriers to deliver curcumin into cell nuclei provides the possibility of fast
and efficient intranuclear delivery of pharmaceutically active substances bypassing enzymatic degradation in the
lysosomes.
To confirm the assumption that it is the small-size fraction of nanocarriers that is responsible for fast dynamin-
independent curcumin uptake to all cellular compartments, we removed the small-size fraction of the nanocarriers
using an Amicon centrifugal filter device with 30 kDa molecular weight cut-off. As can be seen in Figure 2 (cf.
solid and dashed lines in panel B), nanoparticles with the average diameters below 50 nm were efficiently removed.
Similar to the size distribution obtained by the emulsion method, we obtained a mean size of 200 nm, median
of 170 nm and SD of 80 nm. Cell studies performed with the filtered fraction showed that it acts in the same
way as emulsion-prepared nanocarriers (Figure 8) and its delivery was efficiently stopped by preincubating cells in
dynasore (data not shown).
The interaction of the PVP-OD curcumin nanocarriers with average diameters greater than 50 nm obtained via
filtration with CRL 2429 fibroblast and U87 glioblastoma cell cultures in the absence of endocytosis inhibitors was
subsequently studied. Figure 8 clearly demonstrates that these larger nanocarriers are no longer able to enter the
nuclei of the cell.
It is well known that the size of nanocarriers strongly affects cellular uptake [53]. However, this phenomenon is
considered to be primarily related to the features of the endocytic pathway, in particular the optimal bending curva-
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Figure 8. Uptake of filtered curcumin-loaded nanocarriers. Fluorescence images showing CRL 2429 (A) and U87 (B)
cells after incubation with curcumin-loaded PVP-OD nanocarriers produced by the suspension method and then
filtered using 30 molecular weight cut-off centrifugal filter units. From left to right: Curcumin (517 nm, yellow) and
Hoechst (465 nm, blue) fluorescence channels, the composite image and 2D histograms showing colocalization of
fluorophores in the channels and the respective Pearson correlation coefficient.
ture of the membrane, required to drive the membrane-wrapping process and the formation of an invagination [53].
This process is also affected by the number of available targeting moieties on the surface of the nanoparticle
interacting with receptors on the cell surface. However, in our case the uptake process is not affected by the
presence of uptake inhibitors and the nanocarriers do not possess any specific targeting moieties. This implies a
nonendocytic pathway for the cellular uptake of nanocarriers. This is a relatively understudied field where the
main focus has been the application of cell-penetrating peptides as functional moieties [54]. It has been found that
certain cell-penetrating peptides are capable of inducing nonendocytic uptake of their cargo through transient
destabilization of a membrane and formation of a pore suitable for transportation of a relatively large cargo [55,56].
On the other hand, modeling studies have shown that amphiphilic nanoparticles (so-called Janus particles) are also
capable of direct translocation through the membrane [57] and pore formation [58] facilitating uptake of further
particles. Evidently, such mechanisms pave the way for particle penetration not only through the cell membrane but
also into other intracellular compartments, including the nucleus. Interestingly, such indiscriminate penetration of
small polymeric nanocarriers throughout cell compartments has been observed in [59], however, the authors have
not performed inhibition studies, and hence it remains unclear whether the uptake process was endocytic or not.
Although further studies are necessary to identify the exact uptake mechanism, the fact that polymeric nanocarriers
with average diameters less than 50 nm exhibit a different cell penetration mechanism opens the exciting possibility
of delivering pharmaceutically active substances to various cell compartments including the cell nucleus.
Conclusion
It was shown that the amphiphilic PVP-OD is capable of forming nanocarriers in aqueous media at concentrations
exceeding 0.065 mmol/l, as well as of solubilizing highly hydrophobic compounds such as curcumin. Two of the
most commonly used methods for drug loading – emulsification and ultrasonic dispersion – were successfully
employed and found to lead to the formation of carriers with different particle size distributions and, more
importantly, a distinctively different biological effect. Specifically, the emulsion-produced nanocarriers were found
to lack sub-100 nm particles, which were abundant in the dispersion-produced nanocarriers. Using the U87
glioblastoma and CRL 2429 fibroblast cells as model systems, we found that nanocarriers produced via the
emulsion route penetrate cells by endocytic mechanisms. On the other hand, sub-100 nm nanocarriers produced
by ultrasonic dispersion were found to cross cellular membranes via nonendocytic mechanisms with a very fast
kinetics. They were observed to deliver the model hydrophobic drug throughout all cellular compartments including
the nucleus. This opens the intriguing possibility to deliver pharmaceutically active substances into cell nuclei by
merely tailoring the size of polymeric carriers.
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Summary points
• Amphiphilic thiooctadecyl-terminated poly-N-vinyl-2-pyrrolidone (PVP-OD) was synthesized by radical
polymerization and nuclear magnetic resonance and IR spectroscopy were employed to fully characterize the
produced polymer.
• It was demonstrated that PVP-OD is capable of emulsifying hydrophobic compounds at low concentration.
• Two commonly used drug-loading methods – emulsification and ultrasonic dispersion – were successfully applied
to form nanocarriers loaded with curcumin-model pharmaceutically active hydrophobic compound used in the
study.
• It was shown that these two loading methods lead to different size distribution, where ultrasonic dispersion
contains large fraction of sub-100 nm particles.
• Uptake studies employing glioblastoma and fibroblasts as well as two uptake inhibitors – dynasore and
wortmannine – were carried out.
• It was found that the nanocarriers produced by the emulsification method penetrate the cells via
dynamin-dependent endocytosis and cannot enter the nucleus, while ultrasonic dispersion penetrates cells by
diffusion and delivers hydrophobic drug throughout all cell compartments including the nucleus.
• Elimination of sub-100 nm fraction from the suspension-produced nanocarriers also removes the ability to
penetrate cell nuclei.
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